help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on November 27, 2002, doi:10.1164/rccm.200209-1116OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200209-1116OCv1
167/9/1232    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Currie, G. P.
Right arrow Articles by Lipworth, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Currie, G. P.
Right arrow Articles by Lipworth, B. J.
American Journal of Respiratory and Critical Care Medicine Vol 167. pp. 1232-1238, (2003)
© 2003 American Thoracic Society

Effects of Montelukast on Surrogate Inflammatory Markers in Corticosteroid-treated Patients with Asthma

Graeme P. Currie, Daniel K. C. Lee, Kay Haggart, Caroline E. Bates and Brian J. Lipworth

Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom

Correspondence and requests for reprints should be addressed to Dr. Brian J. Lipworth, M.B.Ch.B., Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, Scotland, UK. E-mail: b.j.lipworth{at}dundee.ac.uk

We evaluated whether montelukast conferred additive effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone. Twenty-two patients with mild to moderate asthma completed a double-blind, placebo-controlled study. After a 2-week run-in using FP 250 µg/SM 50 µg 1 puff twice daily, patients entered a randomized crossover period to receive additional montelukast 10 mg daily or placebo for 3 weeks each. For the first 2 weeks, they received FP/SM 1 puff BID, and then they received FP 250 µg 1 puff BID for the 3rd week. The primary outcome was adenosine monophosphate challenge threshold and recovery time; secondary outcomes included surrogate inflammatory markers and lung function. Compared with FP/SM run-in, adding montelukast to FP/SM was better (p < 0.05) than placebo for inflammatory markers but not for lung function. For adenosine monophosphate threshold, recovery, exhaled nitric oxide, and blood eosinophils, there were 1.4 (95% confidence interval, 1.1–1.8) geometric mean fold, 10 minutes (3–17 minutes), 2.1 parts per billion (0.2–3.9 parts per billion), and 88 (34–172) x 106/L differences, respectively. The combination of FP plus montelukast was superior to FP/SM for inflammatory markers but was inferior for lung function. Thus, in patients taking FP/SM or FP, montelukast conferred complimentary effects on surrogate inflammatory markers, which were dissociated from lung function. Further studies are required to evaluate whether these effects of montelukast translate into clinical benefits.

Key Words: asthma therapy • leukotriene receptor antagonist • salmeterol • fluticasone




This article has been cited by other articles:


Home page
 Ther Adv Respir DisHome page
M. M. del Giudice, A. Pezzulo, C. Capristo, E. Alterio, S. Caggiano, D. de Benedictis, and A. F. Capristo
Leukotriene modifiers in the treatment of asthma in children
Therapeutic Advances in Respiratory Disease, October 1, 2009; 3(5): 245 - 251.
[Abstract] [PDF]

Home page
 Ther Adv Respir DisHome page
L. Bjermer
Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits
Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 149 - 161.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Deykin, M. E. Wechsler, H. A. Boushey, V. M. Chinchilli, S. J. Kunselman, T. J. Craig, E. DiMango, J. V. Fahy, M. Kraft, F. Leone, et al.
Combination Therapy with a Long-Acting beta-Agonist and a Leukotriene Antagonist in Moderate Asthma
Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 228 - 234.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. P. Currie, D. K. C. Lee, D. Menzies, and B. J. Lipworth
Evaluating the Effects of "Triple Therapy" With Inhaled Corticosteroids, Long-Acting {beta}2-Agonists, and Leukotriene Modifiers in Asthma.
Chest, July 1, 2006; 130(1): 301 - 302.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. R. Zeidler, E. C. Kleerup, J. G. Goldin, H. J. Kim, D. A. Truong, M. D. Simmons, J. W. Sayre, W. Liu, R. Elashoff, and D. P. Tashkin
Montelukast improves regional air-trapping due to small airways obstruction in asthma
Eur. Respir. J., February 1, 2006; 27(2): 307 - 315.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. A. Biernacki, S. A. Kharitonov, H. M. Biernacka, and P. J. Barnes
Effect of Montelukast on Exhaled Leukotrienes and Quality of Life in Asthmatic Patients
Chest, October 1, 2005; 128(4): 1958 - 1963.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. P. Currie, D. K. C. Lee, and P. Srivastava
Long-Acting Bronchodilator or Leukotriene Modifier as Add-on Therapy to Inhaled Corticosteroids in Persistent Asthma?
Chest, October 1, 2005; 128(4): 2954 - 2962.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. C. Fardon and B. J. Lipworth
An Own GOAL or a Real Breakthrough?
Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1060 - 1060.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. P. Currie and D. K. C. Lee
The GOAL Study Designed to Favor a Long-acting {beta}2-Agonist?
Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1060 - 1061.
[Full Text] [PDF]

Home page
 BMJHome page
G. P Currie, G. S Devereux, D. K C Lee, and J. G Ayres
Recent developments in asthma management
BMJ, March 12, 2005; 330(7491): 585 - 589.
[Full Text] [PDF]

Home page
 QJMHome page
G.P. Currie, P. Srivastava, O.J. Dempsey, and D.K.C. Lee
Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists
QJM, March 1, 2005; 98(3): 171 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L. Jayaram, M. Duong, M. M. M. Pizzichini, E. Pizzichini, D. Kamada, A. Efthimiadis, and F. E. Hargreave
Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma
Eur. Respir. J., January 1, 2005; 25(1): 41 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G.P. Currie and D.K.C. Lee
Methacholine and macrolides
Eur. Respir. J., October 1, 2004; 24(4): 709 - 710.
[Full Text] [PDF]

Home page
 ChestHome page
S. Steinshamn, M. Sandsund, M. Sue-Chu, and L. Bjermer
Effects of Montelukast and Salmeterol on Physical Performance and Exercise Economy in Adult Asthmatics With Exercise-Induced Bronchoconstriction
Chest, October 1, 2004; 126(4): 1154 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. S. Mendes, M. A. Campos, A. Hurtado, and A. Wanner
Effect of Montelukast and Fluticasone Propionate on Airway Mucosal Blood Flow in Asthma
Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1131 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. K. C. Lee, C. M. Jackson, K. Haggart, and B. J. Lipworth
Repeated Dosing Effects of Mediator Antagonists in Inhaled Corticosteroid-Treated Atopic Asthmatic Patients
Chest, April 1, 2004; 125(4): 1372 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 265 - 276.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2003 American Thoracic Society 		  SOTA, FL